Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Efinopegdutide

Stage Phase 1Stale

Sponsor Merck Sharp & Dohme LLC

Route oral and injection

Class GLP-1/glucagon

Mechanism GLP-1 and glucagon receptor co-agonist

Sources

registry, as of 2025-02-26Stale

https://clinicaltrials.gov/study/NCT06701305

A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015). Overall status COMPLETED. Phases PHASE1. Lead sponsor Merck Sharp & Dohme LLC. Enrollment 48. Conditions Healthy. The goal of this study is to learn about the safety of efinopegdutide (MK-6024) and how well overweight healthy people tolerate it. Researchers also want to know what happens to efinopegdutide in a person's body over time when taken as a single dose (Part 1) or as multiple doses

ClinicalTrials.gov NCT06701305 protocol and results modules

publication, as of 2023-09-18Stale

https://pubmed.ncbi.nlm.nih.gov/37355043/

patients with non-alcoholic fatty liver disease. This study assessed the effects of the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide relative to the selective GLP-1 receptor agonist semaglutide on liver fat content (LFC) in patients with non-alcoholic fatty liver disease (NAFLD). This was a phase IIa, randomize

PMID 37355043

Studies

A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)

Registry NCT06701305

Phase Phase 1

Status Completed

Enrollment 48

Start 2024-06-13

Primary completion 2025-02-18

Study completion 2025-02-18

Catalyst Primary completion. 2025-02-18. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part 1: Efinopegdutide

Comparator placebo

Population Healthy

Part 1: Placebo

Population Healthy

Part 2: Efinopegdutide

Comparator placebo

Population Healthy

Part 2: Placebo

Population Healthy